Background. Chronic granulomatous disease (CGD) is a rare genetic disorder causing recurrent infections. More than one-quarter of patients develop hepatic abscesses and liver dysfunction. Recent reports suggest that disease-modifying treatment with corticosteroids is effective for these abscesses. Comparison of corticosteroid therapy to traditional invasive treatments has not been performed.
Chronic granulomatous disease (CGD) is a rare genetic disorder affecting approximately 1 in 250 000 live births in the United States [1] . These patients suffer from recurrent bacterial and fungal infections secondary to impaired phagocyte respiratory burst resulting from inherited mutations in 1 of 5 phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase genes: gp91 phox (CYBB, approximately 65% of patients), p22 phox (CYBA, <5%), p47 phox (NCF1, 30%), p67 phox (NCF2, <5%), and p40 phox (NCF4, 2 cases) [2] . Initially considered fatal, prophylactic antibiotics, antifungals, interferon-γ, and recently, bone marrow transplantation have significantly improved disease prognosis. Most patients now live into adulthood [3, 4] .
Despite improved mortality, morbidity associated with CGD remains significant. While most infectious complications are pulmonary, almost a third of CGD patients will suffer from liver abscesses [4] [5] [6] and an associated worse overall survival [7] . Hepatic abscesses in CGD are phenotypically distinct from the pyogenic liver abscesses associated with other conditions. They present as septate masses surrounded by a thick pseudocapsule containing inspissated fluid and amorphous cell debris [6] . While surgical resection of abscesses refractory to multimodality antibiotic treatment is effective and associated with a low mortality, surgical morbidity may affect 56% of cases, leading some to favor debridement and percutaneous drainage when possible [6, [8] [9] [10] . Overall, the high incidence of, and the inability to accurately predict, recurrence has kept clinical management empiric.
Recently, our group examined the heterogeneity in clinical phenotype and outcomes of CGD patients in correlation with residual neutrophil function. Survival was positively correlated with higher residual reactive oxygen intermediate (ROI) levels. Superoxide production by quartiles (Q1, Q2, Q3, Q4) ranged from 0.26 to 0.94, 0.95 to 1.67, 1.70 to 2.71, and 2.72 to 60.5, respectively [2] . p47 phox mutations were associated with higher ROI levels and had commensurately better survival than severe gp91 phox mutations [2] .
Liver abnormalities such as increased alkaline phosphatase and thrombocytopenia were also major determinants of outcome [2] . Nodular regenerative hyperplasia, portal hypertension, liver fibrosis, and liver abscesses conspire to make liver dysfunction a strong predictor of mortality [2, [5] [6] [7] . These data suggest that liver inflammation and manipulation are likely modifiable factors influencing outcome. Treatment of CGD-associated liver abscesses with highdose corticosteroids and targeted intravenous antibiotics is an emerging approach that simultaneously modifies underlying inflammatory aberrancies while treating infection [11, 12] . Initial results in small case series have been promising, but have not compared corticosteroids to conventional management. Here, we compare biochemical and clinical outcomes between CGD patients with liver abscesses treated with open surgery (OS), interventional radiology (IR), or corticosteroid management (CM). We found improved liver function tests and reduced need for repeat surgical intervention in CM cases, suggesting that invasive therapy may not be optimal for all CGD liver abscesses.
METHODS
With approval from the institutional review board (IRB), review of prospectively maintained databases identified 268 patients with CGD treated at the National Institutes of Health Clinical Center (NIH/CC) from 1980 to 2014. Eighty-eight patients (32%) demonstrated liver involvement (Figure 1 ). Forty-eight of 88 patients lacked records of either prior liver abscesses or had management of liver abscesses carried out at an outside institution, and were excluded. Patients whose initial diagnosis was later changed or who died due to complications related to bone marrow transplant were also excluded. There was a small proportion of patients treated with multimodality antimicrobial therapy and supportive care only. Thirty-two (36%) with complete medical records and follow-up underwent at least 1 procedure or further intervention for liver involvement, either in the form of OS, IR, or CM (Figure 1 ).
Patients were admitted to the NIH/CC under the National Institute of Allergy and Infectious Diseases (NIAID). Patients with CGD-associated liver abscesses diagnosed from clinical history and appropriate imaging were evaluated by hepatology and surgical consultant services. After full records review, clinicopathological information captured during the initial multidisciplinary treatment of each patients' liver abscess(es) included age at both CGD diagnosis and respective liver intervention, previously performed liver procedures, available computed tomography or magnetic resonance imaging (MRI), and laboratory studies including pre-and posttreatment liver function tests and pretreatment erythrocyte sedimentation rate (ESR). The pretreatment values were obtained at admission.
Measurement of NADPH oxidase activity and detection of ROI levels by myeloperoxidase-dependent hydrogen peroxide production or superoxide-dependent ferricytochrome-c reduction stimulated by phorbol esters was performed as previously described [2] . NADPH oxidase germline mutation analysis was performed according to standardized procedures and adherence to IRB guidelines, with all patients providing written consent.
Interventions for liver abscesses included open surgical procedures (OS) (liver abscess debridement/drainage, nonanatomical liver wedge resection, segmentectomy, or lobectomy), percutaneous interventional radiologic procedures (IR), and high-dose corticosteroid management (CM). CM as primary management included a median dose of 1 mg/kg/day (range, 0.6-1.8 mg/kg/day) of prednisone or methylprednisolone subsequently tapered over a median of 5 months (range, 1-7 months). CM included concurrent targeted antimicrobial therapy guided by mandatory aspiration cultures and directed by the treating infectious disease specialist.
Time to repeat hepatic intervention was defined as time from previous treatment (OS, IR, CM) to repeat intervention by either OS or IR. Of note, some patients received both IR and OS procedures at the NIH/CC and are included in each respective treatment arm based on the admission during which they received that treatment. All patients included in the CM cohort had received a prior intervention (either IR or OS) for liver involvement in the past at an outside institution. These patients are included in the respective treatment cohort based upon the treatment received during each admission.
Paired Student t, χ 2 , Kruskal-Wallis, and Mann-Whitney tests were utilized to compare variables between the individual groups. Patients with no further hepatic intervention were censored at date of last follow-up. The Kaplan-Meier method was used to calculate intervention-free and overall survival rates, then compared using log-rank (Mantel-Cox) analysis. Pearson r linear correlation coefficient test was used to measure the linear correlation between the variables ROI and time to repeat hepatic intervention. All statistical analyses were performed using Microsoft Excel 2016 or GraphPad Prism version 6.0 software.
RESULTS

Chronic Granulomatous Disease Patients With Liver Abscesses Undergo a Variable Number of Liver-Directed Procedures
Of 268 patients captured between 1980 and 2014 at our institution, 32 were reported with liver involvement and had complete clinicopathological information with continuous follow-up ( Figure 1 ). Table 1 summarizes baseline clinicopathological variables including ROI levels and NADPH genotype of patients who underwent either IR, OS, or CM. The number of liver procedures ranged from 1 to 13 with an average of 3.7 procedures per patient. At any given intervention, patients had a mean number of 2.5 liver abscesses (range, 1-13) with a mean diameter of 3.5 cm (range, [1] [2] [3] [4] [5] [6] [7] [8] . ESR, as a marker of severity of inflammation, was recorded at admission with mean preintervention ESR of 69 mm/hour (range, 10-145 mm/hour; normal range, 0-25 mm/hour). Median follow-up was 15.5 years (8.5-32.9 years of follow-up), with 18 patients (69%) alive at final analysis. Seven patients underwent ≥4 procedures. In patients who underwent <4 procedures compared with patients who underwent 4 or more liver interventions, neither abscess number (average, 2 in both groups, P = .28), abscess size (3.5 vs 3 cm, P = .56), nor ESR level (78 vs 66 mm/hour, P = .17) differed.
Prolonged Time to Repeat Hepatic Intervention in Patients Who Underwent Open Surgery Compared to Percutaneous Procedures
One hundred liver procedures were performed on 26 patients with CGD-associated liver abscesses, including 42 IR (15 patients) and 58 OS (22 patients) ( Figure 3A ). Overall survival was calculated from last liver treatment. Median overall survival was not met in either cohort and there was no difference in overall survival between the groups (P = .12; Figure 3B ). Ninety-day mortality rate following IR procedure was 4.7%. One patient suffered intracerebral hemorrhage secondary to disseminated intravascular coagulopathy and another died of overwhelming sepsis 1.37 months following percutaneous drainage. Ninety-day mortality following OS was 1.7%. One patient died 0.9 months following open debridement from overwhelming sepsis.
Corticosteroid Management of Liver Abscesses in Chronic Granulomatous Disease Patients Is Associated With Fewer Subsequent Hepatic Interventions
Identification of patients with liver abscesses not amenable to OS or IR motivated therapy with high-dose corticosteroids and targeted antimicrobial therapy [11, 12] . Representative hepatic imaging of successful CM is shown in Figure 4 . Characteristics of patients treated with corticosteroids and targeted antimicrobial therapy are listed in Table 1 . The CM cohort had a mean of 4.86 abscesses (range, 2-14), higher than the IR (P = .02) but not different than the OS (P = .14) cohort. There was no difference in CM compared to IR or OS regarding size of the largest abscess, admission ESR levels, or baseline antimicrobial prophylaxis. Of patients in the OS, IR, and CM cohorts with available record, 89%, 100%, and 100% were on trimethoprim-sulfamethoxazole, and 41%, 70%, and 86% were on antifungal prophylaxis. The number of patients receiving prophylactic interferon-γ therapy at abscess occurrence was small and not different among the groups. Microbiology from Figure 3C ). Overall survival between the OS/IR and CM groups was similar (P = .12) ( Figure 3D ).
Improved Biochemical Response in Chronic Granulomatous Disease Patients With Liver Disease Treated With Corticosteroids
We next examined liver function across the 3 treatment modalities, hypothesizing that either steroidal inflammatory modulation or removal of diseased liver volume would improve liver function laboratory values. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase (ALP), and total bilirubin levels were analyzed. 
Neutrophil Function Is Associated With Surgical Outcome Time to Repeat Hepatic Intervention in Chronic Granulomatous Disease Patients With Liver Abscesses
Previous work established residual neutrophil superoxide production as prognostic for overall survival in CGD [2] . A cutoff of 2.3 nmol superoxide/10 6 cells/hour in conjunction with mean fluorescence intensity of neutrophil dihydrorhodamine oxidation of 225 arbitrary units discriminated between survival outcomes. Additionally, each quartile of increased residual superoxide production correlated with improved survival [2] . To determine whether the intervention-free interval correlated with neutrophil function, we examined the relationship between residual ROI levels and time to repeat hepatic intervention ( Figure 5A ). There was a linear correlation between these 2 variables (r = 0.6, P = .0019), and the association between elevated ROI levels and prolonged intervention-free interval was noted as a trend in Kaplan-Meier analysis ( Figure 5B and 5C Figure 5D ).
DISCUSSION
Great strides have been made in understanding the pathophysiology and underlying genetics of CGD, and elucidation of causative germline defects has allowed early detection, prognostication, and risk stratification. Recently, understanding the prognostic significance of neutrophil function and the end organ damage from dysfunctional immune cell activation has led to a more rational approach to treatment [2, 5-7, 12, 13] . This is particularly true of hepatic involvement, and degree of liver dysfunction is a strong predictor of adverse outcomes in CGD [5] [6] [7] . Histopathological correlates of liver dysfunction in CGD patients are portal hypertension, nodular regeneration, and fibrosis [5] , with portal hypertension being a known cause of decreased bacterial clearance [14] . In CGD, increased bacterial translocation from impaired intestinal barrier function and lowered hepatic immune surveillance may predispose to the development of liver abscesses [7] . We demonstrate that medical management of CGDassociated liver abscesses with corticosteroids and antibiotics is associated with prolonged intervention-free interval compared with procedural intervention. We hypothesize that steroid-induced reduction of systemic inflammation reduces immune infiltration and capillary leak of the central venules, improving portal hypertension and liver function with decreasing portovenous shunting, thereby restoring the preabscess immune milieu. The use of pharmacotherapies against deranged inflammatory responses in conditions other than CGD have reduced the need for procedural intervention and improved survival. For example, in ulcerative colitis, caused by abnormal T helper cell type 2 (Th2) response, timely treatment with high-dose corticosteroids followed by maintenance immunosuppression has been shown to reduce mortality compared to placebo [15] . Also, reduction in need for surgery and complications such as toxic megacolon has been noted with immune-modulating therapy in ulcerative colitis [16, 17] . The improved outcome in patients treated with corticosteroids in combination with antimicrobials might also be explained by better tissue penetration of the antimicrobial agents due to a less inflamed environment, in particular in the surrounding pseudocapsule of the liver abscess.
We studied 26 CGD patients suffering liver involvement with a median complete follow-up of 15.5 years and an average of 3.7 liver-directed treatments (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) in the form of OS, IR, or CM.
OS management of liver abscesses was associated with a longer intervention-free interval than IR procedures. Unlike pyogenic abscesses, hepatic abscesses in CGD are frequently multiloculated ( Figure 6A) , with viscous contents, and a thickened pseudocapsule ( Figure 6B ). While MRI may help characterize the dense granulation associated with these abscesses [10] , their unique characteristics appear to be difficult to treat by an IR approach [6] .
In our study, the intervention-free interval was associated with improved postprocedure ALP levels in OS and CM patients, though ALP in the IR cohort did not improve. This is significant, as elevated ALP has been associated with increased mortality in patients with CGD [7] . While it is conceivable that the removal of additional "at-risk" liver tissue during surgical resection could explain the observed improvements in ALP in OS compared to IR, we saw no difference in intervention-free interval between major liver resections vs limited debridements/nonanatomical wedge resections (1.17 vs 1.6 years, P = .99). While the relatively small number of patients undergoing major liver surgery (n = 7) could have limited detection of a difference, the improvement in ALP in both CM and OS adds biochemical support to the hypothesis that intervention-free interval (improved in both OS and CM cohorts compared with IR) is an important measure of disease course and clinical outcome. It is interesting to note that neutrophil function as assessed by ROI in CGD patients with liver involvement who underwent additional liver-directed therapy was lower than in those managed medically [2] . This observation is in line with later findings showing neutrophil function to be correlated with outcome of liver-directed therapy, with patients with higher ROI levels having prolonged intervals to repeat hepatic interventions (r = 0.6, P < .05). Our study is limited by being performed in a single center, its retrospective nature, and the empiric determination of need for hepatic intervention. Management was directed by a multidisciplinary team of CGD experts, surgeons, hepatologists, and interventional radiologists. The OS and IR groups were balanced, including baseline neutrophil function and severity. In contrast, the corticosteroid group had higher preoperative ALP levels and more abscesses, which was in part what necessitated nonoperative interventions. These increased markers of severity affirm the favorable results of corticosteroid intervention. Similarly, a trend of worse neutrophil function was noted in the steroid group than in the interventional groups (mean ROI levels, 2.12 for OS and IR vs 1.64 for CM, P = .202). The high rate of patients with incomplete records and follow-up is a concern for the introduction for potential bias. However, to provide well-documented, uninterrupted follow-up and accurately calculate intervention-free intervals, we included only patients with complete records.
CONCLUSIONS
This retrospective study of patients with CGD liver abscesses demonstrates that patients treated with corticosteroids and targeted antimicrobial therapy had longer times to subsequent hepatic intervention than those managed by open surgical or percutaneous drainage. Steroid therapy was also associated with improvement in liver function abnormalities and unassociated with mortality. These observational data, derived from a large prospective cohort, suggest that nonoperative approaches to CGD liver abscess are not only safe and effective, but may preserve liver health, ameliorating a major cause of late morbidity and mortality in CGD. 
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